Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 3Other hematologic neoplasm 2Gynecologic 2Genitourinary 2Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 98Specimen Handling 79pembrolizumab 75enzalutamide 63Nivolumab 59Gemcitabine 54Docetaxel 50apalutamide 42Radiosurgery 41Abiraterone Acetate 40Androgen Antagonists 39Prednisone 38Biopsy 37darolutamide 35Cisplatin 35cabozantinib 31Radiotherapy 31Carboplatin 28Pluvicto 27abiraterone 26enfortumab vedotin 24Ipilimumab 24Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 18X-Rays 18Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ceralasertib × Genitourinary × 90 days × Clear all
NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

University of California, San Francisco

Phase 2 Active not recruiting
83 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03787680 2026-03-23

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
49 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡